Skip to Content

Belluscura makes 'considerable progress’ 

Belluscura makes 'considerable progress’ 

LONDON and PLANO, Texas – Belluscura shipped or received orders for 2,850 X-PLOR portable oxygen concentrators by Dec. 31, 2022, the company stated in a trading update for the year. 

The company anticipates its adjusted EBITDA loss will be in line with market expectations. Its retained cash balances of $1.8 million amounted to $11.9 million, with inventory and inventory deposits. 

"During the year we have made considerable progress,” said CEO Robert Rauker. “We have enhanced our production, quality accreditation and supply chain, positioning us well to deliver on the demand we are seeing for our devices, as we expand our distribution partners and geographical reach. Market reception for the next generation X-PLOR and Nomad App has been extremely positive, with an encouraging level of forward orders. We are very excited about the upcoming launch of the DISCOV-R, which we believe will be a transformational product, and we look to the future with confidence." 

Belluscura expects to launch the first DISCOV-R POCs for pre-market evaluation in the first quarter, with full commercialization anticipated in the second quarter. The company says the DISCOV-R is the first ambulatory pulse-dose and two-liter continuous flow POC in the world. It also says the unit, which weighs less than any comparable dual-flow oxygen concentrator on the market, produces nearly three times the oxygen by weight than its competition.   

Among other highlights in the update: 

  • Belluscura completed its transition to U.S.-based manufacturing by July 2022, paving the way for the company to produce 536 X-PLOR POCs in its in-house facility. With Innomax coming online in the first quarter of 2023, it expects to more than double production of the units. 
  • The company’s collaboration agreement with the VGM Group has resulted in 17 new distribution agreements in the last three months, including an agreement with a leading DME provider and distributor in the US that serves 2 million patients online and through 1,000 locations. 

Read about how Belluscura is doubling down on the POC market.  


To comment on this post, please log in to your account or set up an account now.